Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Novelty in the target landscape of the pharmaceutical industry

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Percentage of targets by competitive space.
Figure 2: Competition on novel targets by latest development phase.
Figure 3: Novel targets across the 10 largest pharmaceutical companies.

References

  1. DiMasi, J. A. & Faden, L. B. Competitiveness in follow-on drug R&D: a race or imitation? Nature Rev. Drug Discov. 10, 23–27 (2011).

    Article  CAS  Google Scholar 

  2. Agrawal, V. & Jamwal, S. Top ten global pharma. World Pharmaceutical Frontiers [online], (2011).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pankaj Agarwal.

Ethics declarations

Competing interests

The authors are all employeees of GlaxoSmithKline.

Related links

FURTHER INFORMATION

Pharmaprojects

PowerPoint slides

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agarwal, P., Sanseau, P. & Cardon, L. Novelty in the target landscape of the pharmaceutical industry. Nat Rev Drug Discov 12, 575–576 (2013). https://doi.org/10.1038/nrd4089

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4089

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research